Health
Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients – News-Medical.Net
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or…
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or lessen disease severity in patients with COVID-19 who were hospitalized but had a relatively moderate case, a new study finds. All…
Continue Reading
-
Noosa News23 hours agoBrisbane man, 39, dies after stabbing at inner city home in early morning attack, prompting investigation
-
General24 hours agoTwo British MPs refused entry into Israel, UK foreign ministry says
-
Noosa News20 hours agoMeasles alert issued across popular south-east attractions
-
General14 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts